Literature DB >> 26732801

Prospective clinical and serological follow-up in early childhood reveals a high rate of subclinical RSV infection and a relatively high reinfection rate within the first 3 years of life.

A Kutsaya1, T Teros-Jaakkola2, L Kakkola1, L Toivonen2, V Peltola2, M Waris1, I Julkunen1.   

Abstract

Children encounter repeated respiratory tract infections during their early life. We conducted a prospective clinical and serological follow-up study to estimate the respiratory syncytial virus (RSV) primary infection and reinfection rates in early childhood. Sera were collected from 291 healthy children at the ages of 13, 24 and 36 months and antibody levels against RSV antigens were determined by enzyme immunoassay. The RT-PCR method was also used for identifying the possible presence of RSV in symptomatic patients. At ages 1, 2 and 3 years, 37%, 68% and 86%, respectively, of studied children were seropositive for RSV. In children seropositive at age 1 year, RSV reinfection rate was at least 37%. Only one of reinfected children showed evidence for a third reinfection by age 3 years. Of children who turned RSV seropositive between ages 1 and 2 years, the reinfection rate was 32% during the third year of life. The mean antibody levels at primary infection were very similar in all age groups. The average decrease of antibody levels was 25-30% within a year. In 66 cases RSV infection was identified by RT-PCR. RSV infection rate in early childhood is 86% and reinfection rate is around 35%. This prospective serological follow-up study also provided evidence for the presence of RSV infections in children that did not show clinical signs warranting RSV RNA detection.

Entities:  

Keywords:  Antibodies; RSV; infants; reinfection; seroprevalence

Mesh:

Substances:

Year:  2016        PMID: 26732801      PMCID: PMC9150639          DOI: 10.1017/S0950268815003143

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  28 in total

1.  Serum antibody decay in adults following natural respiratory syncytial virus infection.

Authors:  Ann R Falsey; Harjot K Singh; Edward E Walsh
Journal:  J Med Virol       Date:  2006-11       Impact factor: 2.327

2.  The transmission dynamics of groups A and B human respiratory syncytial virus (hRSV) in England & Wales and Finland: seasonality and cross-protection.

Authors:  L J White; M Waris; P A Cane; D J Nokes; G F Medley
Journal:  Epidemiol Infect       Date:  2005-04       Impact factor: 2.451

3.  Antigenic variations of respiratory syncytial virus in recurrent infections.

Authors:  P Pothier; S Ghim; T B Bour; J B Gouyon; M Dauvergne
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

Review 4.  Active and passive immunisation against respiratory syncytial virus.

Authors:  M Zambon
Journal:  Rev Med Virol       Date:  1999 Oct-Dec       Impact factor: 6.989

Review 5.  Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment.

Authors:  J B Domachowske; H F Rosenberg
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

6.  Severity of respiratory syncytial virus infection is related to virus strain.

Authors:  E E Walsh; K M McConnochie; C E Long; C B Hall
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

7.  The antibody response to primary and secondary infection with respiratory syncytial virus: kinetics of class-specific responses.

Authors:  R C Welliver; T N Kaul; T I Putnam; M Sun; K Riddlesberger; P L Ogra
Journal:  J Pediatr       Date:  1980-05       Impact factor: 4.406

8.  Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.

Authors:  J R Groothuis; E A Simoes; M J Levin; C B Hall; C E Long; W J Rodriguez; J Arrobio; H C Meissner; D R Fulton; R C Welliver
Journal:  N Engl J Med       Date:  1993-11-18       Impact factor: 91.245

9.  Subgrouping of respiratory syncytial virus strains from Australia and Papua New Guinea by biological and antigenic characteristics.

Authors:  J C Hierholzer; G A Tannock; C M Hierholzer; R A Coombs; M L Kennett; P A Phillips; I D Gust
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

10.  The natural history of respiratory syncytial virus in a birth cohort: the influence of age and previous infection on reinfection and disease.

Authors:  E O Ohuma; E A Okiro; R Ochola; C J Sande; P A Cane; G F Medley; C Bottomley; D J Nokes
Journal:  Am J Epidemiol       Date:  2012-10-11       Impact factor: 4.897

View more
  17 in total

1.  Epidemiology of respiratory syncytial virus in a community birth cohort of infants in the first 2 years of life.

Authors:  Mari D Takashima; Keith Grimwood; Peter D Sly; Stephen B Lambert; Keith J Chappell; Daniel Watterson; Robert S Ware
Journal:  Eur J Pediatr       Date:  2021-02-25       Impact factor: 3.183

2.  Influenza A Reinfection in Sequential Human Challenge: Implications for Protective Immunity and "Universal" Vaccine Development.

Authors:  Matthew J Memoli; Alison Han; Kathie-Anne Walters; Lindsay Czajkowski; Susan Reed; Rani Athota; Luz Angela Rosas; Adriana Cervantes-Medina; Jae-Keun Park; David M Morens; John C Kash; Jeffery K Taubenberger
Journal:  Clin Infect Dis       Date:  2020-02-14       Impact factor: 9.079

3.  Serological Follow-Up Study Indicates High Seasonal Coronavirus Infection and Reinfection Rates in Early Childhood.

Authors:  Pekka Kolehmainen; Jemna Heroum; Pinja Jalkanen; Moona Huttunen; Laura Toivonen; Varpu Marjomäki; Matti Waris; Teemu Smura; Laura Kakkola; Sisko Tauriainen; Ville Peltola; Ilkka Julkunen
Journal:  Microbiol Spectr       Date:  2022-06-21

4.  Retrospective Parameter Estimation and Forecast of Respiratory Syncytial Virus in the United States.

Authors:  Julia Reis; Jeffrey Shaman
Journal:  PLoS Comput Biol       Date:  2016-10-07       Impact factor: 4.475

5.  Defining the vaccination window for respiratory syncytial virus (RSV) using age-seroprevalence data for children in Kilifi, Kenya.

Authors:  Joyce U Nyiro; Ivy K Kombe; Charles J Sande; James Kipkoech; Patience K Kiyuka; Clayton O Onyango; Patrick K Munywoki; Timothy M Kinyanjui; D James Nokes
Journal:  PLoS One       Date:  2017-05-22       Impact factor: 3.240

6.  Age-Specific Profiles of Antibody Responses against Respiratory Syncytial Virus Infection.

Authors:  Nao Jounai; Megumi Yoshioka; Miyuki Tozuka; Kazue Inoue; Tatsuya Oka; Kazuki Miyaji; Katsuyasu Ishida; Naoki Kawai; Hideyuki Ikematsu; Chiaki Kawakami; Hiroyuki Shimizu; Masaaki Mori; Ken J Ishii; Fumihiko Takeshita
Journal:  EBioMedicine       Date:  2017-01-16       Impact factor: 8.143

7.  First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults.

Authors:  Paola Cicconi; Claire Jones; Esha Sarkar; Laura Silva-Reyes; Paul Klenerman; Catherine de Lara; Claire Hutchings; Philippe Moris; Michel Janssens; Laurence A Fissette; Marta Picciolato; Amanda Leach; Antonio Gonzalez-Lopez; Ilse Dieussaert; Matthew D Snape
Journal:  Clin Infect Dis       Date:  2020-05-06       Impact factor: 9.079

8.  Antigenic Site-Specific Competitive Antibody Responses to the Fusion Protein of Respiratory Syncytial Virus Were Associated With Viral Clearance in Hematopoietic Cell Transplantation Adults.

Authors:  Xunyan Ye; Obinna P Iwuchukwu; Vasanthi Avadhanula; Letisha O Aideyan; Trevor J McBride; Laura L Ferlic-Stark; Kirtida D Patel; Felipe-Andres Piedra; Dimpy P Shah; Roy F Chemaly; Pedro A Piedra
Journal:  Front Immunol       Date:  2019-03-29       Impact factor: 7.561

Review 9.  Contribution of Cytokines to Tissue Damage During Human Respiratory Syncytial Virus Infection.

Authors:  Karen Bohmwald; Nicolás M S Gálvez; Gisela Canedo-Marroquín; Magdalena S Pizarro-Ortega; Catalina Andrade-Parra; Felipe Gómez-Santander; Alexis M Kalergis
Journal:  Front Immunol       Date:  2019-03-18       Impact factor: 7.561

10.  Molecular Characterization of Respiratory Syncytial Virus in Children With Repeated Infections With Subgroup B in the Philippines.

Authors:  Michiko Okamoto; Clyde P Dapat; Ann Marie D Sandagon; Leilanie P Batangan-Nacion; Irene C Lirio; Raita Tamaki; Mayuko Saito; Mariko Saito-Obata; Socorro P Lupisan; Hitoshi Oshitani
Journal:  J Infect Dis       Date:  2018-08-24       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.